The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL
Martin Dyer
• 4 Dec 2015
Martin Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase Ib study of venetoclax (ABT-199) and obinutuzumab, an anti-CD20 antibody, in relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL). The preliminary data show patients achieving minimum residual disease (MRD) states with no toxicity.
